Category: Parkinson’s Disease: Clinical Trials
Objective: To demonstrate safety and effectiveness of adaptive deep brain stimulation (aDBS) algorithms in participants with Parkinson’s disease (PD) in China.
Background: aDBS has been recently approved in the United States, Europe and other regions for the treatment of PD. Building on these findings, the ADAPT-PD China study will evaluate the safety and effectiveness of aDBS in PD participants in China who are receiving stable continuous DBS (cDBS) therapy.
Method: The ADAPT-PD China Study is a prospective, multicenter, open label, single arm clinical trial designed to evaluate the effectiveness of aDBS for Parkinson’s Disease (PD) in China. Eligible participants will have been previously implanted with a primary cell or rechargeable commercial DBS system capable of sensing local field potentials (LFPs). An investigational feature will be unlocked to allow programming of two aDBS modes (Single Threshold or Dual Threshold) using low frequency (8-30 Hz) LFP control signals. Participants will enter a 30-day Baseline Phase in their existing cDBS programming configuration, followed by an aDBS Randomization, Set-up and Adjustment Phase. During the aDBS Setup visit, both modes will be programmed and evaluated in a randomized, single-blind sequence, with a minimum of one-week ambulatory trial for each mode to identify the “Best” aDBS mode. Participants who tolerate either aDBS modes will enter a one-month aDBS Evaluation Phase using the “Best” aDBS mode followed by the Long-Term Follow-up Phase for over 11 months. Evaluations will include measures of Good “On” Time (“On” time without troublesome dyskinesias), quality of life, movement, sleep, patient preference and satisfaction.
Results: Participants are currently enrolling at five investigational sites, with at least 33 participants expected to complete the aDBS Evaluation Phase. The primary effectiveness endpoint will measure Good “On” Time from the motor diary. Other endpoints will include MDS-UPDRS, EQ-5D-5L, PDSS-2, PDQ-39, LED, chronic LFP data, programming data, patient preference and satisfaction. Safety will include evaluation of stimulation-related adverse events.
Conclusion: This multi-center, chronic aDBS study is expected to generate evidence on the safety and effectiveness of aDBS therapy in participants with PD in China.
To cite this abstract in AMA style:
H. Shang, B. Sun, J. Wu, Y. Zhang, N. Zhang, A. Xie, L. Chen, J. Zhang, Y. Tan, T. Goble, H. Berrier, S. Stanslaski. Evaluating Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease in the Chinese Population (ADAPT-PD China Study) [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/evaluating-adaptive-dbs-algorithm-for-personalized-therapy-in-parkinsons-disease-in-the-chinese-population-adapt-pd-china-study/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluating-adaptive-dbs-algorithm-for-personalized-therapy-in-parkinsons-disease-in-the-chinese-population-adapt-pd-china-study/